Efficacy and safety of bepridil for prevention of ICD shocks in patients with Brugada syndrome and idiopathic ventricular fibrillation

International Journal of Cardiology

Volumn 168, Issue 5, 2013, Pages 5083-5085

  Aizawa, Yoshiyasu ^a   Yamakawa, Hiroyuki ^a   Takatsuki, Seiji ^a   Katsumata, Yoshinori ^a   Nishiyama, Takahiko ^a   Kimura, Takehiro ^a   Nishiyama, Nobuhiro ^a   Fukumoto, Kotaro ^a   Tanimoto, Yoko ^a   Tanimoto, Kojiro ^a   Mitamura, Hideo ^b   Ogawa, Satoshi ^c   Fukuda, Keiichi ^a  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Federation of National Public Service Personnel Mutual Aid Associations   (Japan)

^c International University of Health and Welfare Mita Hospital   (Japan)

Author keywords

Bepridil; Brugada syndrome; ICD; Ventricular fibrillation

Indexed keywords

BEPRIDIL;

ADULT; AGED; BRUGADA SYNDROME; CLINICAL ARTICLE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART VENTRICLE FIBRILLATION; HUMAN; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; LETTER; MALE; PRIORITY JOURNAL; RECURRENT DISEASE; SECONDARY PREVENTION; ST SEGMENT ELEVATION; UNSPECIFIED SIDE EFFECT;

BEPRIDIL; BRUGADA SYNDROME; ICD; VENTRICULAR FIBRILLATION;

ADULT; AGED; ANTI-ARRHYTHMIA AGENTS; BEPRIDIL; BRUGADA SYNDROME; COHORT STUDIES; DEFIBRILLATORS, IMPLANTABLE; ELECTRIC INJURIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VENTRICULAR FIBRILLATION;

EID: 84886382969     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2013.07.187     Document Type: Article

References (6)

1. B. Belhassen, A. Glick, and S. Viskin Efficacy of quinidine in high-risk patients with Brugada syndrome Circulation 110 2004 1731 1737
2. Y. Mizusawa, H. Sakurada, M. Nishizaki, and M. Hiraoka Effects of low-dose quinidine on ventricular tachyarrhythmias in patients with Brugada syndrome: low-dose quinidine therapy as an adjunctive treatment J Cardiovasc Pharmacol 47 2006 359 364
3. M. Sugao, A. Fujiki, and K. Nishida Repolarization dynamics in patients with idiopathic ventricular fibrillation: pharmacological therapy with bepridil and disopyramide J Cardiovasc Pharmacol 45 2005 545 549
4. M. Murakami, K. Nakamura, and K.F. Kusano Efficacy of low-dose bepridil for prevention of ventricular fibrillation in patients with Brugada syndrome with and without SCN5A mutation J Cardiovasc Pharmacol 56 2010 389 395
5. L. Kang, M.Q. Zheng, M. Morishima, Y. Wang, T. Kaku, and K. Ono Bepridil up-regulates cardiac Na + channels as a long-term effect by blunting proteasome signals through inhibition of calmodulin activity Br J Pharmacol 157 2009 404 414
6. H. Takanari, H. Honjo, and Y. Takemoto Bepridil facilitates early termination of spiral-wave reentry in two-dimensional cardiac muscle through an increase of intercellular electrical coupling J Pharmacol Sci 115 2011 15 26